© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Coherus Oncology, Inc. (CHRS) shows an Average True Range (ATR) of 0.16 and an Enterprise Value of 607.22M. Its average trading volume over the past 3 months is 2.03M, indicating liquidity. These fundamental metrics provide insight into CHRS's underlying financial health and market activity.
| ATR | 0.16 |
| Enterprise Value | 607.22M |
| Avg Vol (3 Months) | 2.03M |
| Avg Vol (10 Days) | 1.35M |
Coherus Oncology, Inc. (CHRS) technical indicators as of February 26, 2026: the SMA 20 is -13.68%, SMA 50 at -1.58%, and SMA 200 at 29.37%. The RSI 14 value is 44.03, suggesting its current momentum. These technical analysis signals help assess CHRS's price trends and potential future movements.
| SMA 20 | -13.68% |
| SMA 50 | -1.58% |
| SMA 200 | 29.37% |
| RSI 14 | 44.03 |
Coherus Oncology, Inc. (CHRS) stock performance overview as of February 26, 2026: The 52-week high is $2.62 (currently -35.77% below), and the 52-week low is $0.71 (currently 136.62% above). Over the past year, CHRS's performance is 9.15%, compared to the S&P 500's 10.91% change.
| 52-Week High | 2.62 |
| 52-Week High Chg | -35.77% |
| 52-Week Low | 0.71 |
| 52-Week Low Chg | +136.62% |
| S&P 500 52-Week Chg | 10.91% |
According to market data, Coherus Oncology, Inc. (CHRS) stock's recent performance metrics show that over the last month, CHRS is 14.81%, with a Year-to-Date (YTD) performance of 9.15%. Over the past year, the stock has seen a 9.15% change. These figures summarize CHRS's price movements across various periods, reflecting its historical returns.
| Period | 1 Week | 1 Month | Quarter | Half Year | 1 Year | YTD |
|---|---|---|---|---|---|---|
| High | 1.74 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 |
| Low | 1.59 | 1.58 | 1.09 | 1.09 | 0.71 | 1.35 |
| Performance | -6.06% | +14.81% | -6.06% | +74.79% | +9.15% | +9.15% |
According to current financial data, CHRS stock's P/E (TTM) ratio is 1.26, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.23. Key valuation ratios for CHRS, including P/S (2.44), P/B (2.23), and P/FCF (-2.26), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | CHRS | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | 1.26 | -1.23 | -5.16 | 32.59 |
| P/S (TTM) | 2.44 | 3.71 | 464.92 | 5.98 |
| P/B (TTM) | 2.23 | 0 | 9 | 5.26 |
| P/FCF (TTM) | -2.26 | -6.31 | -253.28 | 30.85 |